{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Condition&page=48", "query": { "condition": "Skin Condition", "page": 48 }, "page_size": 10 }, "pagination": { "page": 48, "page_size": 10, "total_count": 16298, "total_pages": 1630, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Condition&page=49&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Skin+Condition&page=47&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T17:05:31.174Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06330064", "title": "A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent or Metastatic Solid Tumors" ], "interventions": [ { "name": "Ifinatamab deruxtecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 680, "start_date": "2024-04-10", "completion_date": "2028-07-25", "has_results": false, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-10-30T17:05:31.174Z", "location_count": 18, "location_summary": "Los Angeles, California • Whittier, California • Skokie, Illinois + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Skokie", "state": "Illinois" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06330064" }, { "nct_id": "NCT00039793", "title": "Massage Therapy for Cancer-Related Fatigue", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms", "Ovarian Neoplasms", "Prostatic Neoplasms", "Colorectal Neoplasms" ], "interventions": [ { "name": "Moderate-intensity and low-intensity bodywork therapy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "National Center for Complementary and Integrative Health (NCCIH)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2001-03", "completion_date": "2004-03", "has_results": false, "last_update_posted_date": "2006-08-18", "last_synced_at": "2026-10-30T17:05:31.174Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00039793" }, { "nct_id": "NCT00640614", "title": "Clinical Evaluation of T.R.U.E. TEST® : Safety and Efficacy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Contact Dermatitis" ], "interventions": [ { "name": "T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Allerderm", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 235, "start_date": "2008-04", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2020-05-05", "last_synced_at": "2026-10-30T17:05:31.174Z", "location_count": 4, "location_summary": "Little Rock, Arkansas • Shawnee Mission, Kansas • Louisville, Kentucky + 1 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Shawnee Mission", "state": "Kansas" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Mineola", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00640614" }, { "nct_id": "NCT05457816", "title": "Genetic and Social Network Correlates of Rheumatoid Arthritis Outcomes in Hispanic Populations: A Prospective Study", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [], "intervention_types": [], "sponsor": "National Human Genome Research Institute (NHGRI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 28, "start_date": "2022-11-21", "completion_date": "2024-01-09", "has_results": false, "last_update_posted_date": "2024-01-19", "last_synced_at": "2026-10-30T17:05:31.174Z", "location_count": 2, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05457816" }, { "nct_id": "NCT07311993", "title": "Phase 1 Study of CLR 125 in Triple Negative Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Iopofosine I 131", "type": "DRUG" }, { "name": "CLR 125", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cellectar Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2025-12-05", "completion_date": "2029-07", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-30T17:05:31.174Z", "location_count": 4, "location_summary": "Jacksonville, Florida • Glen Burnie, Maryland • Rochester, Minnesota + 1 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Glen Burnie", "state": "Maryland" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Princeton", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT07311993" }, { "nct_id": "NCT00565721", "title": "A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High-grade Glioma", "Lung Cancer", "Head & Neck Cancer", "Sarcoma", "Melanoma" ], "interventions": [ { "name": "Fluciclatide Injection - (AH111585 (F18))", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GE Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2007-11", "completion_date": "2012-09", "has_results": true, "last_update_posted_date": "2014-08-18", "last_synced_at": "2026-10-30T17:05:31.174Z", "location_count": 1, "location_summary": "Princeton, New Jersey", "locations": [ { "city": "Princeton", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00565721" }, { "nct_id": "NCT00003269", "title": "Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Drug/Agent Toxicity by Tissue/Organ", "Lung Cancer", "Lymphoma", "Ovarian Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "amifostine trihydrate", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Scripps Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 20, "start_date": "1998-02", "completion_date": "2001-01", "has_results": false, "last_update_posted_date": "2011-01-10", "last_synced_at": "2026-10-30T17:05:31.174Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003269" }, { "nct_id": "NCT03860883", "title": "Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cutaneous Melanoma, Stage II" ], "interventions": [ { "name": "Wide Local Excision = 1cm Margin", "type": "PROCEDURE" }, { "name": "Wide Local Excision = 2cm Margin", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Melanoma and Skin Cancer Trials Limited", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2998, "start_date": "2019-12-17", "completion_date": "2034-12-31", "has_results": false, "last_update_posted_date": "2024-11-27", "last_synced_at": "2026-10-30T17:05:31.174Z", "location_count": 128, "location_summary": "Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 99 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03860883" }, { "nct_id": "NCT05298254", "title": "A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Herpes Simplex" ], "interventions": [ { "name": "Non-adjuvanted HSV formulation 1", "type": "BIOLOGICAL" }, { "name": "Non-adjuvanted HSV formulation 2", "type": "BIOLOGICAL" }, { "name": "Non-adjuvanted HSV formulation 3", "type": "BIOLOGICAL" }, { "name": "HSV formulation 1 with adjuvant 1", "type": "BIOLOGICAL" }, { "name": "HSV formulation 2 with adjuvant 1", "type": "BIOLOGICAL" }, { "name": "HSV formulation 3 with adjuvant 1", "type": "BIOLOGICAL" }, { "name": "HSV formulation 1 with adjuvant 2", "type": "BIOLOGICAL" }, { "name": "HSV formulation 2 with adjuvant 2", "type": "BIOLOGICAL" }, { "name": "HSV formulation 3 with adjuvant 2", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "HSVTI_F1", "type": "BIOLOGICAL" }, { "name": "HSVTI_F2", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 505, "start_date": "2022-03-07", "completion_date": "2025-06-12", "has_results": false, "last_update_posted_date": "2025-09-08", "last_synced_at": "2026-10-30T17:05:31.174Z", "location_count": 6, "location_summary": "Phoenix, Arizona • Wichita, Kansas • Kansas City, Missouri + 3 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Rochester", "state": "New York" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05298254" }, { "nct_id": "NCT02005666", "title": "To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acne Vulgaris" ], "interventions": [ { "name": "Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel", "type": "DRUG" }, { "name": "DUAC® Gel", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zydus Lifesciences Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "12 Years to 40 Years" }, "enrollment_count": 850, "start_date": "2013-11", "completion_date": "2016-09-28", "has_results": true, "last_update_posted_date": "2020-10-14", "last_synced_at": "2026-10-30T17:05:31.174Z", "location_count": 12, "location_summary": "Dinuba, California • Santa Ana, California • Boynton Beach, Florida + 9 more", "locations": [ { "city": "Dinuba", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "Boynton Beach", "state": "Florida" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02005666" } ] }